NCT00431353View on ClinicalTrials.gov

VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

325

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Cytomegalovirus Infections
Interventions
DRUG

Ganciclovir

5mg/kg iv bid for 21 days

DRUG

valganciclovir [Valcyte]

900mg po bid for 21 days

Trial Locations (50)

4

Dublin

1001

Auckland

1040

Caracas

1070

Brussels

1090

Vienna

2010

Darlinghurst

2145

Sydney

4001

Maracaibo

4031

Basel

4032

Chermside

4102

Woolloongabba

10000

Zagreb

10617

Tallinn

11000

Belgrade

20230

Aguascalientes

34126

Istanbul

34662

Istanbul

35100

Izmir

35128

Padua

48903

Barakaldo

51014

Tartu

67100

Coppito

110076

New Delhi

13086-970

Campinas

90020-090

Porto Alegre

01323-900

São Paulo

04038-002

São Paulo

05403-900

São Paulo

05651-901

São Paulo

T6G 2B7

Edmonton

M5G 1L7

Toronto

600 004

Chennai

226 014

Lucknow

632 004

Vellore

LV-1002

Riga

06720

Mexico City

Unknown

Oslo

Madrid

San Cristóbal de La Laguna

85-094

Bydgoszcz

80-211

Gdansk

60-479

Poznan

02-006

Warsaw

50-417

Wroclaw

41-800

Zabrze

03010

Alicante

08907

Barcelona

07000

Antalya

L7 8XP

Liverpool

OX3 7LJ

Oxford

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00431353 - VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients | Biotech Hunter | Biotech Hunter